AUTHOR INDEX TO VOLUME 60

Alzuet G, 219
Baquial JGL, 133
Bednarski PJ, 1
Behere DV, 245
Beraldo H, 163
Bereman, RD, 149
Bogitsh BJ, 277
Bonomo RP, 205
Borrás J, 219
Buglyó P, 45
Calahorro CV, 199
Carraway AD, 267
Carter CE, 277
Casanova J, 219
Ciancaglini P, 155
Coe EM, 149
Connelly, GP, 31
Culeddu N, 45
Danyi P, 69
Demartin F, 233
Demicheli C, 163
Díaz Díez M, 199
Dodoff N, 257
Fiol JJ, 109
Ganadu ML, 233
Gao F, 61
García Barros FJ, 199
Garcia-Granda S, 219
Garnier-Suillerot A, 163
Grancharov K, 257
Houston ML, 267
Ianelli S, 89
Jasionowski M, 21
Johnston DS, 267
Jones MM, 277
Kiss T, 45
Kowalik-Jankowska T, 21
Kozlowski H, 21
Lane JE, 277
Lankiewicz L, 21
Latorre J, 219
Lenkinski RE, 31
Leone FA, 155
Lichtenstein A, 187
Liu G, 123
Lubinu G, 233
MacColl R, 175
Machado FC, 163
Marchelli R, 205
Margalit R, 187
Mazza P, 89
Micera G, 45, 69
Molenda JJ, 277
Monte WT, 149
Nagano H, 289
Naldini L, 233
Nomiya K, 289
Norkus E, 299
Oda M, 289
Onindo CO, 21
Orcesi M, 89
Pahari D, 245
Panfil A, 109
Panzanelli A, 233
Parsons J, 175
Patel AB, 245
Pelizzi C, 89
Pelizzi G, 89
Peterson J, 267
Pettit LD, 21
Pizauro JM, 155
Povlock SL, 267
Reklaitis J, 299
Rodriques RR, 277
Rubin Y, 31
Sabat M, 109
Sakuma S, 289
Sanaú M, 219
Sanna D, 45,69
Schön I, 69
Shao W, 123
Singh PK, 277
Sorenson JRJ, 133
Sóvágó I, 69
Spassovska N, 257
Sun HY, 79
Tabbí G, 205
Tang W, 123
Tang S, 175
Vaitkus R, 299
Várnagy K, 69
Vaškelis A, 299
Wang H, 61
Wang K, 79
Xie J, 61
Yang P, 61
Yokoyama H, 289
Zani F, 89
Zhu S, 123
Zimmerman LJ, 277

SSDI 0162-0134(95)00193-X

SUBJECT INDEX TO VOLUME 60

Alkaline phosphatase, polyoxyethylene-9-lauryl ether-solubilized, cobalt ions and, 155
Aluminum ion, transferrin interaction, 175
Aluminum(III) complexes, absorption and circular dichroism study, 163
2-Amino-2-deoxy-D-glycero-L-gluco heptonic acid, potentiometric study with divalent metal ions, 199
Amino acids
  sugar á-, equilibria study of divalent metal ions with, 199
  sulfur-containing, cisplatin analog bearing estrogenic 1,2-diarylethylenediamine ligand and, 1
Anhydrotetracycline, metal complexes of, 163
Antimicrobial properties, organotin compounds, 89
Antiprotozoal drugs, development, 277
Apo-transferrin, aluminum ion interaction with, 175
Axial ligand replacement, effects on cytochrome *c*, 123
Burn treatment, liposome-encapsulated silver sulfadiazine, 187
Cadmium^{2+} binding, to erythrocyte spectrin, 79
Cadmium(II), equilibria study with sugar á-amino acid, 199
Calcium and lanthanide ions, with N-acetylaspartate complexes, 31
Calcium depleted horseradish peroxidase, tryptophan sensitized bound terbium(III) fluorescence and, 245
Chagas' disease, *Trypanosoma cruzi* and, 277
Chelating agent inhibition, *Trypanosoma cruzi* epimastigotes, 277
4-Chlorobenzoic acid hydrazides, platinum(II) complexes, 257
Cimetidine, PPH_3AUU and, 233
Cisplatin
  analog reactions, 1
  platinum(II) complexes of 4-methoxy- and 4-chlorobenzoic acid hydrazides and, 257
Cobalt ions, polyoxyethylene-9-lauryl ether-solubilized alkaline phosphatase and, 155
Cobalt(II) complexes
  equilibria study with sugar á-amino acid, 199
  with norfloxacin, 61
Copper(II) complexes
  equilibria study with sugar á-amino acid, 199
  H_2O_2 interaction, 205
  peptide hormones containing disulfide bridges, 69
  saccharose and glycerol, 299
  sulfathiazole, 219
Copper(II)$_2$(3,5-diisopropylsalicylate)$_4$, pharmacological activities, 133
Copper(II) ions, binding by leucine-enkaphalin analogs, 21
Creatinine, nickel(II) complexes with, 109
Cytochrome *c*, axial ligand replacement and, 123
Deferoxamine B, vanadium(IV) and vanadium(V) complexes of, 45
Di-2-pyridylketone 2-aminobenzoylhydrazone, organotin derivatives and, 89
Diamino-diamide type ligands, h_2O_2 interaction with copper(II) complexes with, 205
Diastereoisomeric dipeptides, h_2O_2 interaction with copper(II) complexes with, 205
Dipeptides, diastereoisomeric, h_2O_2 interaction with copper(II) complexes with, 205
Disulfide bridges, peptide hormones containing, 69
Drug encapsulation, thermodynamics, 187
Drug release, kinetics, 187
Erythrocyte spectrin, cadmium^{2+} binding to, 79
Estrogenic 1,2-diarylethylenediamine ligand, cisplatin analog bearing, 1
Ferric heme peptide derivatives, monomeric, 267
Fluorescence, tryptophan sensitized bound terbium(III), calcium depleted horseradish peroxidase and, 245
Glutathione, cisplatin analog bearing estrogenic 1,2-diarylethylenediamine ligand and, 1
Glycerol, copper(II) complex formation with, 299
Gold(I), trisodium salt of bis(thiosalicylato)aurate(I), 289
Heme peptide derivatives, monomeric ferric, 267
Hemoproteins, model systems, 267
H_2O_2 interaction, with copper(II) complexes with diamino-diamide type ligands, diastereoisomeric dipeptides, and tripeptides, 205
Horseradish peroxidase, calcium depleted, 245
Hydrazide derivatives, antibacterial and antifungal activity, 257
Imidazole, cytochrome *c* complexes and, 123
Iron core size, iron dextran complex, 149
Iron dextran complex, solution particle and iron core size, 149
Iron potentials for cytochromes, 123
Iron(III) complexes
  absorption and circular dichroism study, 163
  with norfloxacin, 61
Lanthanide ions, with N-acetylaspartate complexes, 31
Leucine-enkaphalin analogs, copper(II) ions binding by, 21
Ligands, diamino-diamide type, h_2O_2 interaction with copper(II) complexes with, 205
Liposome-encapsulated silver sulfadiazine, infected burn treatment, 187
Magnesium ions, cobalt ions mechanism of action and, 155
Magnesium(II) complexes
  absorption and circular dichroism study, 163
  tetracycline and, 163
Metal complexes, anhydrotetracycline, 163
Metal ions
  aluminum ion interaction with transferrin, 175
  cobalt ions mechanism of action, 155
  equilibria study of divalent, 199
  with N-acetylaspartate complexes, 31
  nickel(II) complexes with creatinine, 109
  vanadium(IV) and vanadium(V) complexes of deferoxamine B, 45
Methionine, cytochrome *c* complexes and, 123
4-Methoxy acid hydrazides, platinum(II) complexes, 257
N-acetylaspartate complexes, calcium and lanthanide ions with, 31
2-(*N-Methyl-N'*-cyano-*N''*-*ethylguanidino*)*Thiotriphenyl*-phophinegold(I), synthesis and structure, 233
NADPH-diaphorase, down-regulation of, 133
Nickel(II) complexes
  with creatinine, 109
  equilibria study with sugar á-amino acid, 199
Nitric oxide synthase, down-regulation of, 133
Norfloxacin, novel iron(III), cobalt(II), and zinc(II) complexes with, 61
Organotin derivatives, di-2-pyridylketone 2-aminobenzoylhydrazone, phenyl(2-pyridyl)ketone 2-aminobenzoylhydrazone, and, 89
Oxovanadium(V) complexes, of deferoxamine B, 45
Oxytocin, copper(II) complexes of, 69
Particle size, iron dextran complex, 149
Peptide derivatives, monomeric ferric heme, 267
Peptide hormones containing disulfide bridges, copper(II) complexes of, 69
Phenyl(2-pyridyl)ketone 2-aminobenzoylhydrazone, organotin derivatives and, 89
Platinum(II) complexes, 4-methoxy- and 4-chlorobenzoic acid hydrazides, 257
Polyoxyethylene-9-lauryl ether-solubilized alkaline phosphatase, cobalt ions and, 155

SSDI 0162-0134(95)00194-8

PPH_3AUU, cimetidine and, 233
Saccharose, copper(II) complex formation with, 299
Silver sulfadiazine, liposome-encapsulated, infected burn treatment, 187
Solution size, iron dextran complex, 149
Spectrin, cadmium² binding to erythrocyte, 79
Sugar á-amino acid, equilibria study of divalent metal ions with, 199
Sulfathiazole, coordination behavior, 219
Superoxide dismutase activity, sulfathiazole and, 219
Tetracycline, magnesium(II) complex and, 163
Thioether bonds, cimetidine, 233
Thiosalicylic acid-Ag(I) complexes, synthesis and characterization, 289
Transferrin, aluminum ion interaction with, 175
Tripeptides, h_2O_2 interaction with copper(II) complexes with, 205
Trisodium salt of bis(thiosalicylato)aurate(I), synthesis and characterization, 289
Trypanosoma cruzi epimastigotes, chelating agent inhibition, 277
Tryptophan sensitized bound terbium(III) fluorescence, calcium depleted horseradish peroxidase and, 245
Vanadium(IV) complexes, of deferoxamine B, 45
Vasopressin, copper(II) complexes of, 69
Zinc ions, cobalt ions mechanism of action and, 155
Zinc(II) complexes
equilibria study with sugar á-amino acid, 199
with norfloxacin, 61